Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer

• Main Authors: Soo Young Jeong (Author), Chel Hun Choi (Author), Tae Joong Kim (Author), Jeong Won Lee (Author), Byoung-Gie Kim (Author), Duk Soo Bae (Author), Yoo-Young Lee (Author)
• Format: Book
• Published: BMC, 2019-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Secondary cytoreductive surgery (SCS) is possible in selected patients with recurrent epithelial ovarian cancer (EOC). The goal of SCS is complete resection, although chemotherapy is always followed. Delayed intervals between primary debulking surgery and adjuvant chemotherapy wa...